{"id":"nafcillin-or-equivalent","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypersensitivity reactions (rash, urticaria)"},{"rate":null,"effect":"Phlebitis at injection site"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Anaphylaxis"}]},"_chembl":{"chemblId":"CHEMBL1568276","moleculeType":"Small molecule","molecularWeight":"454.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nafcillin is a semi-synthetic penicillin that works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It is particularly effective against beta-lactamase-producing Staphylococcus aureus, including methicillin-resistant strains in some cases, making it useful for serious gram-positive infections.","oneSentence":"Nafcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:30.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious infections caused by susceptible Staphylococcus aureus (including methicillin-susceptible strains)"},{"name":"Bacterial endocarditis"},{"name":"Osteomyelitis"},{"name":"Pneumonia"}]},"trialDetails":[{"nctId":"NCT01922011","phase":"PHASE3","title":"Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2013-09-13","conditions":"Acute Hematogenous Osteomyelitis","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Nafcillin (or equivalent)","genericName":"Nafcillin (or equivalent)","companyName":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nafcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious infections caused by susceptible Staphylococcus aureus (including methicillin-susceptible strains), Bacterial endocarditis, Osteomyelitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}